Division of Endocrinology, Department of Medicine and Research Center, Centre hospitalier de l'Université de Montréal (CHUM), 900 Saint-Denis Street, Montréal, QC H2X 0A9, Québec, Canada.
Rev Endocr Metab Disord. 2024 Jun;25(3):619-637. doi: 10.1007/s11154-024-09877-x. Epub 2024 Feb 27.
Adrenal crisis (AC) is a life threatening acute adrenal insufficiency (AI) episode which can occur in patients with primary AI but also secondary AI (SAI), tertiary AI (TAI) and iatrogenic AI (IAI). In SAI, TAI and IAI, AC may develop when the HPA axis is unable to mount an adequate glucocorticoid response to severe stress due to pituitary or hypothalamic disruption. It manifests as an acute deterioration in multi-organ homeostasis that, if untreated, leads to shock and death. Despite the availability of effective preventive strategies, its prevalence is increasing in patients with SAI, TAI and IAI due to more frequent exogenous steroid administration, pituitary immune-related effects of immune checkpoint inhibitors and opioid use in pain management. The delayed diagnosis of acute AI which remains infrequently suspected increases the risk of AC. Its main precipitating factors are infections, emotional distress, surgery, cessation or reduction in GC doses, pituitary infarction or surgical cure of endogenous Cushing's syndrome. In patients not known previously to have SAI/TAI/IAI, recognition of its symptoms, signs, and biochemical abnormalities can be challenging and cause delay in proper diagnosis and therapy. Effective therapy of AC is rapid intravenous administration of hydrocortisone (initial bolus of 100 mg followed by 200 mg/24 h as continuous infusion or bolus of 50 mg every 6 h) and 0.9% saline. In diagnosed patients, preventive education in sick-day rules adjustment of glucocorticoid replacement and hydrocortisone parenteral self-administration must be performed repeatedly by trained health care providers. Strategies to improve the adequate preventive education in patients at risk for secondary AI should be promoted in collaboration with various medical specialist societies and patients support associations.
肾上腺危象(AC)是一种危及生命的急性肾上腺功能不全(AI)发作,可发生于原发性 AI 患者,但也可发生于继发性 AI(SAI)、三发性 AI(TAI)和医源性 AI(IAI)患者。在 SAI、TAI 和 IAI 中,由于垂体或下丘脑破坏,HPA 轴无法对严重应激产生足够的糖皮质激素反应,可能会发生 AC。其表现为多器官稳态的急性恶化,如果不治疗,会导致休克和死亡。尽管有有效的预防策略,但由于更频繁地使用外源性类固醇、免疫检查点抑制剂引起的垂体免疫相关作用以及阿片类药物在疼痛管理中的应用,SAI、TAI 和 IAI 患者的患病率正在增加。急性 AI 的诊断延迟,且仍不常被怀疑,这增加了 AC 的风险。其主要诱发因素是感染、情绪困扰、手术、GC 剂量的停止或减少、垂体梗死或内源性库欣综合征的手术治愈。在以前未被诊断为 SAI/TAI/IAI 的患者中,识别其症状、体征和生化异常具有挑战性,并导致诊断和治疗延迟。AC 的有效治疗是快速静脉给予氢化可的松(初始剂量为 100mg,随后 200mg/24h 持续输注或 50mg 每 6h 静脉推注)和 0.9%生理盐水。在确诊患者中,必须由经过培训的医疗保健提供者反复进行疾病日规则调整、糖皮质激素替代和氢化可的松静脉内自我给药的预防性教育。应与各种医学专家协会和患者支持协会合作,促进针对继发性 AI 风险患者的充分预防性教育策略。
Rev Endocr Metab Disord. 2024-6
Clin Chim Acta. 2020-2-7
Nat Rev Endocrinol. 2024-4
Am J Med. 2016-3
Praxis (Bern 1994). 2018-6
Nat Rev Dis Primers. 2021-3-11
Eur J Endocrinol. 2009-12-2
Rev Endocr Metab Disord. 2021-6
Ann Endocrinol (Paris). 2015-2
Front Endocrinol (Lausanne). 2025-4-22
J Clin Endocrinol Metab. 2016-11
J Clin Endocrinol Metab. 2016-2
Clin Endocrinol (Oxf). 2015-12